|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
the purpose of this study: to evaluate the safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac Lyo", a lyofilizate for preparing solution for intramuscular administration, at various times after vaccination in healthy adult volunteers.
Description: Determination of antibody levels against the SARS-CoV-2 glycoprotein S measured by an ELISA vs. baseline valuesMeasure: The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days Time: at days 0, 14, 21, 28, 42
Description: Determination of Number of Participants With Adverse EventsMeasure: Number of Participants With Adverse Events Time: through the whole study, an average of 180 days
Description: Determination of virus neutralizing antibody titerMeasure: The changing of virus neutralizing antibody titer Time: at days 0, 14, 28, 42
Description: Determination of antigen-specific cellular immunity (specific T-cell immunity, in particular, IFN-gamma production or lymphoproliferation)Measure: The changing of antigen-specific cellular immunity level Time: at days 0, 14, 28
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports